Actively Recruiting
GVM±R in Patients With Relapsed or Refractory Aggressive NHL.
Led by Institute of Hematology & Blood Diseases Hospital, China · Updated on 2025-05-14
115
Participants Needed
1
Research Sites
206 weeks
Total Duration
On this page
Sponsors
I
Institute of Hematology & Blood Diseases Hospital, China
Lead Sponsor
F
First Hospital of China Medical University
Collaborating Sponsor
AI-Summary
What this Trial Is About
This is a prospective clinical study to evaluate the safety and efficacy of GVM±R in patients with relapsed or refractory aggressive non-Hodgkin's lymphoma (NHL).
CONDITIONS
Official Title
GVM±R in Patients With Relapsed or Refractory Aggressive NHL.
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age between 18 and 65 years
- Expected survival of at least 3 months
- Diagnosed with aggressive NHL that is relapsed or refractory after at least one standard therapy or achieved partial response after at least 4 therapy cycles
- At least one measurable lesion according to Lugano 2014 criteria (lymph node >1.5 cm; non-lymph node >1.0 cm)
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2
- Adequate blood counts: ANC ≥1.5x10⁹/L, platelets ≥75x10⁹/L, hemoglobin ≥80 g/L (with relaxed limits if bone marrow involved)
- Adequate liver and kidney function within specified limits
You will not qualify if you...
- Prior treatment with mitoxantrone or mitoxantrone liposomes
- Prior doxorubicin or anthracycline treatment exceeding cumulative doses (doxorubicin >360 mg/m² or equivalent)
- Anti-tumor treatment or participation in other clinical trials within 4 weeks or 5 half-lives before study drug administration
- Autologous or allogeneic hematopoietic stem cell transplantation within 100 days before study drug administration
- Previous chimeric antigen receptor T-cell (CAR-T) therapy
- Hypersensitivity to study drugs or components
- Uncontrolled systemic diseases such as active infection, uncontrolled hypertension, or diabetes
- Significant heart conditions including long QTc, severe arrhythmias, heart failure NYHA grade ≥ III, or recent serious cardiac events
- Active hepatitis B or C infection
- HIV infection
- Other malignant tumors except controlled non-melanoma skin basal cell carcinoma or certain carcinoma in situ without treatment in past 5 years
- Pregnant or lactating women and those unwilling to use contraception
- Grade 3 or higher neuritis
- Active central nervous system lymphoma
- Any other conditions making the subject unsuitable for the study as determined by the investigator
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Institute of Hematology & Blood Diseases Hospital, CAMS & PUMC
Tianjin, Tianjin Municipality, China, 300020
Actively Recruiting
Research Team
W
Wei Liu
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here